$COCP News Article - Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV
https://marketwirenews.com/news-releases/cocr...41066.html